Remember: “One size fits
nothing in ADMET/PK”
- when to use recombinant
versus microsomal CYP inhibition?
- when should you use a
cassette versus discrete PK approach?
- what exactly is PK/PD in
your project?
- can you use the rat alone
to predict human PK?
No matter if your project is
in early drug discovery, lead optimization or already in candidate profiling
during pre-clinical development, CapEval Pharma can help to find the right assay
conditions to improve, fine-tune and/or fully characterize drug-likeness, ADME,
DDI potential and cross-species PK including human PK and dose prediction.
We can help you with: - Evaluation of in silico
data and physicochemical properties
- Proposal for early high throughput ADME assays
- Detailed SOPs and technical help for all
advanced ADME assays
- Metabolite identification incl. CYP or other
enzyme mapping
- Transporter evaluation (substrate and
inhibition format)
- Advice how to approach new 2012 FDA guidance
for DDI
- Metabolites in safety testing (MIST FDA
Guidance)
- Toxicophores and reactive intermediate assays
- New early safety assays (e.g. HCS screening,
Greenscreen)
- CYP induction studies
- Design and conduct of PK experiments (in house
or CRO) for rodents, rabbit, dog,
minipig, NHP
- Target-specific PK/PD approaches
- Allometry, human PK and dose prediction
- Radiolabeled in vitro
met ID in combination with rodent/non-rodent mass balance/metabolite profiling,
QWBA
|